Introduction {#s1}
============

Neural stem cells (NSCs) serve as a source for new neurons in both the developing and adult brain. In the adult rodent brain, NSCs are confined into two locales, namely the subventricular zone (SVZ) of the lateral ventricles and the DG of the hippocampus. NSCs within the DG proliferate and differentiate into granule cells (GCs) eventually integrating into the existing network ([@bib39]). DG NSCs \[also known as radial-glia-like cells (RGLs) ([@bib3]) are distinguished by a unique, tree-like morphology with soma embedded in the subgranular zone (SGZ), a major shaft extending through the adjacent granule cell layer (GCL) and terminating in a dense network of fine cytoplasmic processes spreading in the inner molecular layer ([@bib11]). The functional role of these terminal shafts (if any) has remained obscure.

Stem cell functioning in general, and of RGLs in particular, relies on microenvironmental support by various cellular and extracellular components, collectively referred to as the 'stem cell niche'. Blood vessels (BVs) are considered an integral, indispensable component of stem cell niches, including NSC niches ([@bib20]; [@bib35]). BV may impact stem cell performance by two different modes: via locally released blood-borne substances or via paracrinically acting factors elaborated by the endothelium (\'angiocrine factors\')([@bib33]).

Adult hippocampal RGLs are mostly quiescent but undergo several rounds of cell division upon activation ([@bib8]; [@bib32]). Neurogenic rates are greatly affected by systemic cues, exemplified by exercise-enhanced neurogenesis shown to be mediated by systemic factors ([@bib9]; [@bib21]; [@bib24]). Likewise, heterochronic parabiosis experiments have demonstrated reciprocal influences on neurogenic rates mediated by systemic factors such as CCl11 or GDF11 ([@bib13]; [@bib40]; [@bib42]). Because hippocampal BVs (including those of the DG where RGLs reside) are thought to have a fully-functional BBB, the question arises how are circulating substances accessible to the brain parenchyma without a loss of BBB function?

Both SVZ-resident type B NSCs and DG-resident RGLs were shown to be intimately associated with BVs. In the SVZ, NSCs send a cellular process that wraps a capillary in the nearby striatum ([@bib15]; [@bib20]; [@bib23]). In the DG, RGLs are physically associated with BVs at both the soma side ([@bib10]; [@bib20]; [@bib30]) and the apical side ([@bib20]; [@bib19]; [@bib25]). However, the functional significance of RGL-BV engagements is not well understood. Here we examined the proposition that these RGL processes might serve as a focal conduit through which blood-borne substances can be directly transferred to RGLs in a fully-functional BBB milieu, thereby providing a mechanistic explanation of how can NSCs \'sense\' circulating neurogenic mediators. Additionally, we show that systemically-injected doxorubicin (a BBB-impermeable DNA-intercalating agent used for non-cerebral tumors) can be uptaken by RGLs and provide a direct anti-mitotic mechanism for its anti-neurogenic effect.

Results {#s2}
=======

RGL processes contact endothelial cells in basement membrane-reduced zones {#s2-1}
--------------------------------------------------------------------------

The proposition that the thin processes extended by RGLs can serve as a bridge for transferring blood substances to RGL cell bodies requires that RGL-BV contact points are not separated by pericytes or by a basement membrane (BM) in which endothelial cells are usually invested and also constitutes an important component of the BBB ([@bib37]). Previous studies that used Nestin-GFP to label RGLs ([@bib10]; [@bib25]) were limited by the fact that mural pericytes are also labeled by this reporter (see [Figure 1a](#fig1){ref-type="fig"}; [@bib26]), which makes perivascular pericytes and RGLs indistinguishable at the electron microscopy (EM) level. To overcome this shortcoming, we used *Gli1-cre^ERT2^* mice \[a mouse line in which inducible Cre is not expressed in DG cells other than RGLs ([@bib1]) crossed to Ai9 (TdTomato) reporter line. RGLs were then highlighted with anti-RFP antibody and DAB staining ([Figure 1b](#fig1){ref-type="fig"}) and the tissue processed for EM imaging. Soma of DAB-labeled RGLs in the SGZ were readily discernible by their DAB dark grains ([Figure 1c](#fig1){ref-type="fig"}). At the inner molecular layer in the vicinity of those soma, we identified capillaries that are tightly wrapped by extra-fine (as thin as 30 nm in diameter) RGL processes labeled with DAB ([Figure 1d--g](#fig1){ref-type="fig"}).

![Fine apical processes of RGLs enfold capillary BVs in the inner molecular layer.\
(**a**) 3D reconstruction of the DG of Nestin-GFP mouse co-stained with CD31 for blood vessels. In this line, both RGLs and pericytes (arrows) are GFP-labeled. Please note the contact points of RGLs and blood vessels at both the basal side at the SGZ (1) and the apical side at the inner molecular layer (2). (**b**) *Gli1-Cre^ERT2^* crossed to Ai9 line (inducible TdTomato reporter) received tamoxifen three days before brain retrieval. Immunohistochemistry was done using anti-RFP antibody and DAB labeling. Note that only RGLs are labeled in the DG of this mouse line. (1) basal side, (2) apical side. Scale bar, 50 µm. (**c**) Transmission electron microscopy (TEM) images taken at the SGZ (basal side) showing the soma of two DAB-labeled RGLs (R). The cytoplasm of those cells is detected by DAB dark grains. GC-granule cells. (**d** and **e**) TEM images of the inner molecular layer (apical side) showing two representative examples of a capillary wrapped with DAB-labeled RGL processes. (**f** and **g**) Higher magnification of (**d**) and (**e**) showing that RGLs processes can reach up to 30 nm in thickness. R-RGL; GC-granule cell; E-endothelial cell, RBC-red blood cell; L-blood vessel lumen; P-pericyte.](elife-52134-fig1){#fig1}

The BM is visualized in EM images as a grayish 50--100 nm-thick layer surrounding the abluminal aspect of endothelial cells ([Figure 2a](#fig2){ref-type="fig"}). This component was found to thoroughly encircle DG capillaries of the hilus and outer molecular layer. Strikingly, however, observing endothelial-RGL processes contact points in the inner molecular layer revealed that engagement with BVs takes place in endothelial surfaces distinguished by irregular BM structures (absence of a classical BM appearance), thus allowing for possible direct membrane-to-membrane contact without the barrier imposed by the BM ([Figure 2b](#fig2){ref-type="fig"}). Based on TEM images, we quantified BM coverage at RGL contact points in comparison to areas devoid of RGL and found a significant difference (Fig, 2 c). Only \~30% of vessel abluminal aspect in contact with RGL retain the typical BM structure (as shown in [Figure 2c](#fig2){ref-type="fig"} right).

![Absence of distinctive basement membrane at the contact points between RGLs and endothelial cells in the inner molecular layer.\
TEM images of the same samples as in [Figure 1](#fig1){ref-type="fig"}. (**a**) Representative images of capillaries from the hilus area. Note BM covering the entire capillary abluminal membrane. Please note a double-layered BM at the pericyte (P) contact point and a clear BM at the contact point with an astrocyte (A). Bottom-- higher magnifications. Scale bars: top - 1 µm, bottom- 100 nm. (**b**) Representative images of capillaries taken from the inner molecular layer that associate with DAB-labeled RGLs. Note no characteristic BM at the contact point of RGL (R) with the endothelial cell (E). (**c**) Quantification for the % of BM-covered endothelial abluminal surface with or without contact with RGL. N = 2 animals, 55 images. t(53)=11.51. p=2.37\*10^−5^. Right: Image of BV-RGL contact with evident BM. R-RGL; E-endothelial cell; A-astrocyte; P-pericyte; RBC-red blood cell; L-blood vessel lumen; BM-basement membrane, N-endothelial nucleus.](elife-52134-fig2){#fig2}

We further examined laminin (a vascular BM component)ith immunofluorescence using confocal microscopy ([Figure 3a--d](#fig3){ref-type="fig"}) followed by super-resolution microscopy (stochastic optical reconstruction microscopy -- dSTORM, [Figure 3d'--m](#fig3){ref-type="fig"}). We analyzed images of Gli+ RFP-labeled RGLs in contact with blood vessels ([Figure 3c--i](#fig3){ref-type="fig"}) and found reduced laminin immunofluorescence where RGLs processes were present. In comparison, vessels in the DG not in contact with RGLs ([Figure 3j,k](#fig3){ref-type="fig"}) and cortical vessels ([Figure 3l,m](#fig3){ref-type="fig"}) had more pronounced laminin immunofluorescence. Quantification of dSTORM laminin signals (normalized to vessel wall length) revealed reduced laminin abundance at vessels which included a contact point with RGL in comparison with DG vessels without RGL process or in comparison with cortical vessels ([Figure 3n](#fig3){ref-type="fig"}).

![Reduced laminin expression at the BV-RGL contact point.\
Brain slice of *Gli1-Cre^ERT2^* mouse crossed to Ai9 reporter was immunostained with RFP, CD31 and pan-laminin antibodies. (**a,b**) Confocal image of the DG. (**c,d**) insets of b highlighting BV-RGL contact points. Arrows indicate areas of contact. (**d'**) Super-resolution image of d. The red (568 nm) channel was kept in epi-flaurescence mode to highlight areas of BV-RGL contact. (**e--i**) Representative super-resolution images of capillaries in contact with RGL (arrows). (**J,k**) Representative images of capillaries in the DG not accosicated with an RGL. (**l,m**) Cortical capillaries. (**n,**) Quantification of laminin signal (in dSTORM images) in blood vessels of the DG (with and without a contact with RGL) and in the cortex, normalized to the length of the blood vessel wall (in μm). F(2,29) = 8.221, p=0.001. Post hoc analysis: DG w/RGL vs. DG wo/RGL: p=0.005. DG w/RGL vs cortex: p=0.019.](elife-52134-fig3){#fig3}

Immunofluorescence for a second major protein of the BM, namely collagen IV, also revealed an apparent reduction in its expression in areas of RGL-BV contact ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

Vesicular activity at the RGL-BV contact points {#s2-2}
-----------------------------------------------

The BV-RGL interface was also characterized by robust vesicular activity as many cytoplasmic and abluminal membrane-bound vesicular-like structures (measured 60--100 nm in diameter) were detected there ([Figure 4a--c](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1a](#fig4s1){ref-type="fig"}). To highlight the nature of vesicular structures and to verify that these are transcytotic vesicles, we indtrouced HRP into the blood circulation and stain brain slices with DAB to label the transcytotic vesicular trafficking path. TEM images of capillaries at the inner molecular layer revealed luminal, cytoplasmic and abluminal vesicles containing HRP ([Figure 4d,e](#fig4){ref-type="fig"}). We next aimed to quantify the numbers of HRP-containing vesicles near an RGL. For this purpose, we injected HRP into the tail vein of a Gli1+ RFP-labeled mouse, and performed DAB histochemistry for both structures. Although this double-labeling procedure impaired the integrity of tissue and washed HRP from the vessel lumen, we were able to image and quantify HRP+ endothelial vesicles near a DAB-labeled RGL ([Figure 4---figure supplement 1b,d](#fig4s1){ref-type="fig"}). The density of these vesicles (vesicles/length of the abluminal boundary (μm)) at the BM-modified RGL-BV interface was greater in comparison with BV segments which did not contain an RGL as well as with BV-RGL interface separated by a clear BM ([Figure 4---figure supplement 1c,d](#fig4s1){ref-type="fig"}).

![Vesicular activity at the BV-RGL interface.\
(**a--c**) TEM image of a BV in the inner molecular layer which was stained with anti-RFP antibody as in [Figure 1](#fig1){ref-type="fig"}, to highlight RGLs (R1, R2). BV-RGL contacts were examined for the presence of vesicular-like structures (50--100 nm circular structures at the cytoplasm, luminal and abluminal surfaces). Arrows highlight abluminal membrane-connected and cytoplasmic endothelial vesicles. (**d**) HRP was injected i.v 30 min before brain disection. Representative examples for luminal, cytoplasmic and abluminal HRP-filled vesicles are shown, luminal aspect (dashed orange line), vesicle (blue line) and abluminal boundary (yellow line). Images were taken from endothelial cells at the inner molecular layer. (**e**) TEM of endothelial cells at the inner molecular layer, injected with systemic HRP. Arrows highlight multiple vesicles containing HRP. (**f**) Representative image of an endothelial cell aspect with a continuous BM and no vesicular activity. E-endothelial cell, R-RGL, L-BV lumen, RBC-red blood cell, BM-basement membrane, A- astrocyte.](elife-52134-fig4){#fig4}

In view of these findings, this specialized neurovascular unit (NVU) was further tested for allowing the infiltration of additional systemically-derived molecules.

BBB-impermeable circulatory molecular tracer is uptaken exclusively by hippocampal RGLs {#s2-3}
---------------------------------------------------------------------------------------

Circumventricular organs are known to have permeable vessels to allow for direct exposure of neurons to circulating components. To examine the possibility that other cells in the intact adult brain are \'privileged\' in the sense of having access to blood-borne substances, we injected into the systemic circulation a fluorescently-tagged 10Kd dextran tracer previously shown to be fully contained in the lumen of blood vessels with a functional BBB ([@bib2]; [@bib18]). The tracer (6 mg/kg) was injected to the left ventricle of the heart (the tracer is rapidly cleared in the urine when injected to the tail vein) and the brain was retrieved one minute later and immediately fixed. Inspection of cryosections, co-stained with CD31 to highlight BVs, confirmed that - with the exception of the median eminence of the hypothalamus (a circumventricular organ) and choroid plexus vessels which are known to lack a functional BBB - the tracer is indeed fully retained in nearly all other cerebral BVs ([Figure 5a](#fig5){ref-type="fig"}). As expected, a small population of cells in the DG was labeled ([Figure 5a](#fig5){ref-type="fig"}, top left, and [Figure 5b](#fig5){ref-type="fig"}). These cells had their soma located in the SGZ, i.e., coinciding with the region where RGLs soma reside, and a major shaft extended towards the molecular layer. In fact, both the location and unique morphology of tracer-labeled cells strongly suggested that these are DG RGLs.

![A unique population of cells in the SGZ is specifically labeled by systemically-injected 10Kd dextran tracer.\
(**a**) 10Kd dextran TRITC-labeled tracer was injected to the left heart ventricle of an anesthetized mouse. One minute later the brain was retrieved and immediately fixed. Sections (co-stained with CD31) of the indicated brain areas are presented. Tracer did not infiltrate into cells outside of the vasculature except for a specific population of cells in the SGZ of the DG (arrows), the CP and the median eminence of the hypothalamus (arrow). Scale bars, 50 µm. V-cerebral ventricle. CP -- choroid plexus. (**b**) Representative high magnification image of the DG area in TRITC- 10Kd dextran-injected animal co-immunostained with CD31. Labeled SGZ cells have a radial process that is associated with local blood vessels in the inner molecular layer (arrows). Scale bar, 50 µm. (**c**) Higher magnifications and 3D reconstruction of a dextran-labeled cell and a capillary illustrating mutual contact with no labeling of the extracellular space. The yellow dashed line represents the SGZ. Scale bar, 5 µm.](elife-52134-fig5){#fig5}

We wished to determine whether these cells serve as a conduit allowing direct transfer from the circulation without extracellular leakage into the parenchymal space. We followed the trajectory of tagged cells from a vessel-associated cellular process to soma. Considering its tortuous path, we used Imaris-aided 3D-reconstructions of serial confocal images. As shown in [Figure 5c](#fig5){ref-type="fig"}, there is a clear continuum in tracer presence from the vessel through the major shaft to the soma with no apparent signs of extracellular spillage.

To verify the identity of the tracer-accumulating cells, TRITC-labeled 10Kd tracer was injected into the circulation of mice harboring a Nestin-GFP reporter transgene highlighting RGLs (here, in contrast with EM studies, they can be distinguished from pericytes by their tree-like morphology). As shown in [Figure 6a](#fig6){ref-type="fig"}, due to their fineness, the tracer was barely visible in the tree-like processes and most of it accumulated in the major shaft and soma. We wished to re-confirm that RGLs thin processes also possess the tracer. For this purpose, we injected Nestin-GFP mice with biotin-labeled 10Kd dextran and visualized tracer distribution with Cy3-labeled streptavidin (this procedure was preferred to reduce interference of TRITC signal with GFP fluorescence). Co-localization of biotinylated tracer with nestin-GFP RGLs was evident in both the soma and the apical processes ([Figure 6b](#fig6){ref-type="fig"}).

![DG RGLs uptake a 10Kd systemically-injected dextran tracer.\
(**a**) TRITC-labeled 10Kd tracer was injected into a Nestin-GFP mouse. 3D Imaris reconstruction (right) and confocal z-plane (left, middle) images showing accumulation of the tracer in the soma and major shaft of RGLs. Scale bar, 20 µM. (**b**) Biotin-labeled 10Kd tracer was injected as in (**a**). Sections were stained for CD31 and tracer was highlighted by cy3-labeled streptavidin. Note tracer distribution throughout all RGL processes and soma (arrows), although less strong than the fluorescent tracer. The inset demonstrates the localization of tracer within GFP^+^ RGL fine apical processes. Scale bar, 20 µM.](elife-52134-fig6){#fig6}

Direct uptake of the chemotherapeutic agent doxorubicin by RGLs explains its anti-neurogenic side effects {#s2-4}
---------------------------------------------------------------------------------------------------------

Doxorubicin (dox) is a widely-used chemotherapeutic agent of the Anthracyclines family of DNA -intercalating agents. While inaccessibility of this small molecule (543 Da) to the brain parenchyma ([@bib27]; [@bib38]) has precluded its use for treating brain tumors, its use against other tumors is often associated with significant cognitive impairment, also known as 'chemo brain' (reviewed by [@bib7]). Findings in rodents showing that dox have a dramatic negative effect on DG neurogenesis ([@bib5]; [@bib12]; [@bib14]; [@bib31]) prompted us to examine whether this seemingly paradoxical situation could be explained by direct selective uptake of systemically-administered dox by RGLs. To this end, an experimental protocol similar to the one used for following tracer trafficking was used, except that dox (6 mg/kg) replaced dextran injection. Here we took advantage of the fact that dox have the same fluorescent properties as commonly used red fluorophores thereby enabling its direct visualization in cell nuclei in PFA-fixed brain sections. The fact that systemically-injected dox does not cross to brain parenchyma was validated by showing that in all brain regions known to have a functional BBB, dox was detected only in endothelial cell nuclei (exemplified for the cortex and CA1 region of the hippocampus in [Figure 7a](#fig7){ref-type="fig"}), whereas in areas in which the BBB is inactive, dox-labeled nuclei were also readily detected outside the vasculature (shown for the choroid plexus and the median eminence of the hypothalamus in [Figure 7a](#fig7){ref-type="fig"}). An outstanding exception was dox uptake by RGLs, evidenced by significant labeling of RGL nuclei within 1--2 min from its injection into the circulation of nestin-GFP mice where co-labeling with GFP confirmed the RGL identity of dox-uptaking cells ([Figure 7b and c](#fig7){ref-type="fig"}). We next examined whether dox (being an anti-mitotic agent) has a negative effect on RGL proliferation. For this purpose, we injected dox at the dose of 5 mg/kg into the peritoneal cavity of Nestin-GFP mice (three injections, every other day) followed by three injections of BrdU (50 mg/kg, every 12 hr) to tag proliferating cells ([Figure 8a](#fig8){ref-type="fig"}). Notably, this chronic dox application (in comparison with the previously-used intracardial injection) does not allow for its detection in cell nuclei. Dox treatment did not have an effect on the total numbers of Nestin+ RGL population ([Figure 8b](#fig8){ref-type="fig"}, right), as the majority of those cells are not proliferating. We immunostained for both the proliferation marker Ki67 ([Figure 8b](#fig8){ref-type="fig"}) and for BrdU ([Figure 8c](#fig8){ref-type="fig"}) to detect the proliferating RGL populations. In both cases, the numbers of proliferating RGLs have decreased significantly following dox treatment ([Figure 8b and c](#fig8){ref-type="fig"}). We, therefore, suggest a direct antimitotic effect of dox as a presumable explanation for reduced neurogenesis reported in rodents treated with dox and as a possible factor in the 'chemo-brain' side effect of cancer patients.

![Doxorubicin has limited permeability through BBB capillaries but is being uptaken by RGLs.\
Doxorubicin (200 µg) was injected into the left heart ventricle of Nestin-GFP mice. The brain was retrieved two minutes later. Doxorubicin is integrated into the DNA and detected by self red spectrum fluorescence. (**a**) Immunofluorescence images co-stained with CD31 showing integration of doxorubicin to the nuclei of various brain areas. In areas with intact BBB such as the cortex and the CA1, doxorubicin integrates solely to capillary nuclei. In areas with non-barriered endothelium such as the choroid plexus and the median eminence, doxorubicin is detected externally to blood vessels (arrows). Scale bar, 100 µM. (**b** and **c**) Two representative high-magnification images of the DG demonstrating the integration of doxorubicin to the nuclei of GFP^+^ RGLs. Z-plane projections are shown. Scale bar, 20 µM.](elife-52134-fig7){#fig7}

![Doxorubicin treatment reduces the proliferation rates of Nestin-GFP^+^ RGLs.\
(**a**) Experimental protocol. Doxorubicin (5 mg/kg) or saline were intraperitoneally (I.P) injected to Nestin-GFP mice every other day (3 injections). BrdU (50 mg/kg) was injected I.P. to all animals 3 times at 12 hr intervals before brain retrieval. N = 4 in each group. (**b**) Immunofluorescence images of nestin-GFP DG co-stained with Ki67 (a proliferation marker) and CD31. Arrows highlight Ki67^+^GFP^+^ cells that were verified to have a radial cytoplasmic process (see enlarged z-projection insets). Right: quantification of the total Nestin-GFP RGL population density (top, t(6)=-0.016 p=0.988), Ki67^+^ RGLs density (t(6)=3.398 p=0.015) and the percentage of Ki67^+^ RGLs among total RGLs (t(6)=5.923 p=0.001). (**c**) DG sections were co-stained with BrdU and CD31. Arrows highlight BrdU^+^GFP^+^ cells that were verified to have a radial cytoplasmic process (see enlarged insets). Right: quantification of BrdU^+^ RGLs density (t(6)=7.285 p=3.4\*10^−4^) and the percentage of BrdU^+^ RGLs among total RGLs (t(6)=9.331 p=8.58\*10^−5^). Scale bar for all images, 100 µM.](elife-52134-fig8){#fig8}

Discussion {#s3}
==========

Findings reported here showing that RGL-type NSCs in the adult hippocampus have a \'privileged\' direct access to circulating blood molecules provide a possible mechanistic explanation to the enigmatic situation of NSCs \'sensing\' the presence of particular blood components and responding by adjusting neurogenic rate despite the existence of a fully functional BBB milieu. Circulatory molecules were shown to increase (or decrease) neurogenesis include specific cytokines whose circulatory levels change with age, as well as blood components accumulating in plasma following physical exercise and shown to upregulate DG neurogenesis ([@bib4]; [@bib6]; [@bib9]; [@bib16]; [@bib29]; [@bib36]; [@bib41]). It is likely that additional physiologic cues impacting DG neurogenesis are also mediated by systemic factors making use of this direct gateway to DG RGLs.

Our finding showing that the transfer of blood-borne molecules to RGL cell bodies takes place through RGL's thin cytoplasmic processes ascribes a first known function to the obscure terminal arbor of RGLs. Noteworthy, unlike RGLs, SVZ NSCs failed to uptake injected molecules ([Figure 5a](#fig5){ref-type="fig"}) despite the fact that they also contact BV via a single extended process ([@bib23]). Previously, we and others have shown that cytoplasmic processes extended by RGLs make direct contacts with nearby BVs ([@bib20]; [@bib19]; [@bib25]). Moreover, we showed that VEGF-promoted BV rejuvenation leads to remodeling of the terminal RGL arbor and engagement with even more remote capillaries ([@bib19]). Yet, the functional significance of these physical RGL-BV associations has remained unknown until now.

We show, using EM imaging, that the fine processes of RGLs in the DG make direct contact with the membrane of nearby endothelial cell in the inner molecular layer. This contact takes place in areas with modified/reduced endothelial BM, as shown by both EM imaging and immunofluorescence/super-resolution microscopy. We also highlighted endothelial vesicular activity at the engagement points. While BBB vasculature is known to be poor in vesicular activity ([@bib2]), these findings suggest that this unique connection may allow for systemic molecules to be delivered via vesicular transcytosis directly to the membrane of RGLs. Further studies are required to verify how the transfer of molecules takes place and whether this process is discriminative with regards to specific molecules.

Indiscriminative uptake may explain apparent RGL vulnerabilities to otherwise BBB-impermeable molecules. A notable, clinically-relevant example is that of the BBB-impermeable chemotherapeutic agent doxorubicin. A major side effect of dox is a debilitating cognitive decline affecting a considerable fraction of treated cancer patients ([@bib7]) and animal studies have shown that treatment with dox is manifested in impeded neurogenesis ([@bib5]; [@bib12]; [@bib14]; [@bib34]). However, it has been difficult to reconcile the adverse cerebral side effects of dox with the fact that it is a substrate for p-glycoprotein pumps and is not available to the brain. Our finding that systemically-injected dox is readily and efficiently uptaken by DG RGLs provides a more compelling explanation to this seeming paradox than previous suggestions arguing an indirect mechanism mediated by secondary molecules ([@bib12]; [@bib14]). We show here that the treatment by dox decreases proliferating RGL numbers thus suggesting a cell-autonomous anti-mitotic mechanism.

We conclude that this unique NVU pathway may serve as a gateway for molecules that need to bypass the barrier or a 'hole in the fence' allowing for penetration of molecules that should not enter the brain. We believe that the new mode of delivery of systemic molecules to RGLs uncovered by this study, not only provides a mechanistic explanation to systemic influences on adult hippocampal neurogenesis but may also provide new means of interventional modulations of this important process.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                        Designation                          Source or\                                     Identifiers                                                                 Additional\
  (species) or\                                                                             reference                                                                                                                  information
  resource                                                                                                                                                                                                             
  ---------------------------------------------------- ------------------------------------ ---------------------------------------------- --------------------------------------------------------------------------- ----------------
  Strain, strain background (*Mus musculus* C57Bl/6)   *Nestin-GFP*                         Prof. Grigori Enikolopov, CSHL andStonybrook                                                                               

  Strain, strain background (*Mus musculus* C57Bl/6)   *Gli1-Cre^ERT2^*                     Jax mice                                       strain\                                                                     
                                                                                                                                           007913                                                                      

  Strain, strain background (*Mus musculus* C57Bl/6)   Ai9                                  Jax mice                                       strain 007909                                                               

  Antibody                                             Mouse monoclonal anti BrdU           Serotec                                        PRID:[AB_323427](https://antibodyregistry.org/search.php?q=AB_323427)       1:400

  Antibody                                             Rat monoclonal anti-CD31             Becton Dickinson                               PRID:[AB_393571](https://antibodyregistry.org/search.php?q=AB_393571)       1:50

  Antibody                                             Rabbit polyclonal anti Laminin       Thermo Fischer Scientific                      RRID:[AB_60396](https://scicrunch.org/resolver/AB_60396)                    1:200

  Antibody                                             Rabbit polyclonal anti Collagen-IV   Abcam                                          PRID:[AB_305584](https://antibodyregistry.org/search.php?q=AB_305584)       1:200

  Antibody                                             Rabbit\                              Thermo Fischer Scientific                      PRID:[AB_10979488](https://antibodyregistry.org/search.php?q=AB_10979488)   1:200
                                                       polyclonal Anti Ki67                                                                                                                                            

  Antibody                                             Rabbit polyclonal anti-GFP           Thermo Fischer Scientific                      PRID:[AB_221570](https://antibodyregistry.org/search.php?q=AB_221570)       1:200

  Antibody                                             Rabbit polyclonal anti-RFP           Abcam                                          PRID:[AB_945213](https://antibodyregistry.org/search.php?q=AB_945213)       1:400

  Antibody                                             HRP Anti-Rabbit IgG                  Vector                                         GZ-93951--40                                                                1 drop

  Antibody                                             Chick polyclonal anti RFP            EnCor                                          PRID:[AB_2572308](http://antibodyregistry.org/AB_2572308)                   1:300

  Antibody                                             Donkey anti-mouse Alexa647           Jackson\                                       PRID:[AB_234086](https://antibodyregistry.org/search.php?q=AB_234086)       1:400
                                                                                            Immunoresearch                                                                                                             

  Antibody                                             Donkey anti-rat Alexa647             Jackson Immunoresearch                         PRID:[AB_2340694](http://antibodyregistry.org/AB_2340694)                   1:400

  Antibody                                             Donkey anti-\                        Jackson Immunoresearch                         PRID:[AB_2492288](http://antibodyregistry.org/AB_2492288)                   1:400
                                                       rabbit Alexa647                                                                                                                                                 

  Antibody                                             Donkey anti-rabbit Cy3               Jackson Immunoresearch                         PRID:[AB_2307443](http://antibodyregistry.org/AB_2307443)                   1:400

  Antibody                                             Donkey anti-rabbit Alexa488          Jackson Immunoresearch                         PRID:[AB_2340619](http://antibodyregistry.org/AB_2340619)                   1:400

  Antibody                                             Goat anti-hamster Alexa647           Thermo Fischer Scientific                      PRID:[AB_2535868](http://antibodyregistry.org/AB_2535868)                   1:400

  Antibody                                             Hamster polyclonal anti CD31         Bio-Rad                                        PRID:[AB_321653](http://antibodyregistry.org/AB_321653)                     1:50

  Commercial assay or kit                              Streptavidin Alexa594                Jackson Immunoresearch                         PRID:[AB_2337250](https://antibodyregistry.org/search.php?q=AB_2337250)     1:400

  Commercial assay or kit                              Dab Plus                             Abcam                                          ab103723                                                                    

  Chemical compound, drug                              Florescent mounting medium           Thermo Fischer Scientific                      TA-030-FM                                                                   

  Chemical compound, drug                              DAPI                                 Sigma                                          D9542                                                                       

  Chemical compound, drug                              Tamoxifen                            Sigma                                          T5648                                                                       8 mg/mouse PO

  Chemical compound, drug                              BrdU                                 Sigma                                          B5002                                                                       50 mg/Kg\
                                                                                                                                                                                                                       IP

  Chemical compound, drug                              Doxorubicin                          Sigma                                          44583                                                                       6 mg/kg IC\
                                                                                                                                                                                                                       5 mg/kg IP

  Chemical compound, drug                              HRP                                  Sigma                                          P8250                                                                       10 mg/mouse IV

  Chemical compound, drug                              10Kd Dextran, TRITC                  Molecular Probes                               D1817                                                                       6 mg/Kg\
                                                                                                                                                                                                                       IC

  Chemical compound, drug                              10Kd Dextran, Biotin                 Molecular Probes                               D1956                                                                       6 mg/Kg\
                                                                                                                                                                                                                       IC

  Chemical compound, drug                              GLOX                                 Sigma                                          G2133                                                                       0.5 mg/ml

  Chemical compound, drug                              catalase                             Sigma                                          C30                                                                         40 μg/ml

  Chemical compound, drug                              cysteamine MEA                       Sigma                                          M9768                                                                       10 mM

  Software, algorithm                                  ImageJ                               NIH                                            ThunderSTORM plugin                                                         

  Software, algorithm                                  SPSS                                 IBM                                                                                                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

All animal procedures were approved by the animal care and use committee of the Hebrew University. Transgenic mouse lines that were used in this study (all of C57Bl/6 background): Ai9 and *Gli1-cre^ERT2^* lines were purchased from the Jackson Laboratories (strains 007909, 007913). Nestin-GFP line was obtained from Prof. Grigori Enikolopov, CSHL ([@bib22]). Both males and females aged 2--3 months were used. Animals were grown in SPF housing conditions (4--6 animals per cage) with irradiated rodent food and water ad libitum and 12 hr light/dark cycle. Tamoxifen (Sigma T5648, 40 mg/ml in sunflower seed oil) was administered orally once daily for 2--3 days at a dose of \~8 mg/animal. BrdU (Sigma B5002) was dissolved in saline and injected I.P at 50 mg\\kg every 12 hr (3 injections).

Tracer and doxorubicin injection {#s4-2}
--------------------------------

The following dextran tracers were used (all are lysine fixable): Tritc-labeled 10kD dextran (Molecular Probes, D1817), biotin-labeled 10Kd dextran (D1956). Doxorubicin was obtained from Sigma-Aldrich (44583). All were dissolved in saline to 2 mg/ml and 100 µl (6 mg/kg) was injected into the left heart ventricle 1--2 min before brain retrieval. For chronic use, doxorubicin was injected I.P. at 5 mg/kg every other day, three times.

Tissue processing for immunofluorescence {#s4-3}
----------------------------------------

Brains were fixed by perfusion and immersion in 4% PFA for 5 hr, incubated in 30% sucrose, embedded in OCT Tissue-Tec and cryosectioned to 50 µm floating sections. Coronal slices from all aspects of the rostral-caudal axis were examined. For BrdU staining, brain slices were incubated for 2 hr in 50% formamide/2xSSC at 65°C, 30 min in 2N HCl at 37°C and 10 min in 0.1M boric acid pH8.5. Staining was done as described ([@bib17]) with the following: anti BrdU (Serotec 1:400 PRID:[AB_323427](https://antibodyregistry.org/search.php?q=AB_323427)), anti-CD31 (BD 1:50 PRID:[AB_393571](https://antibodyregistry.org/search.php?q=AB_393571)), anti Laminin (Thermo Scientific 1:200, RRID:[AB_60396](https://scicrunch.org/resolver/AB_60396)), Anti Collagen-IV (Abcam 1:200 PRID:[AB_305584](https://antibodyregistry.org/search.php?q=AB_305584)), Anti Ki67 (Thermo Scientific 1:200, PRID:[AB_10979488](https://antibodyregistry.org/search.php?q=AB_10979488)), anti-GFP (Thermo Scientific 1:200, PRID:[AB_221570](https://antibodyregistry.org/search.php?q=AB_221570)) and anti-RFP (Abcam 1:400, PRID:[AB_945213](https://antibodyregistry.org/search.php?q=AB_945213)). Secondary antibodies were as described in Key Resource Table. Sections were mounted with Permafluor mounting medium (Thermo Scientific, TA-030-FM) with Dapi (Sigma, D9542).

Confocal microscopy was done using Olympus FV-1000 on 20X and X60 objectives and 1.46 µm distance between confocal z-slices. 3d reconstruction images were processed by Bitplane IMARIS 7.6.3 software using the Isosurface function.

Cell proliferation quantification {#s4-4}
---------------------------------

6--7 confocal z-stack images per animal were quantified (N = 4 in every group). The volume of the GCL was calculated by measuring the GCL area in the image (using Olympus FV-10 viewer) and multiplying the measured area by the number of z-axis slices and the distance between slices (1.46 µm). Cells within the GCL (Ki67/CldU/GFP) were counted manually by a blind experimenter (using Olympus FV-10 viewer). Z-plane projections used to verify double labeling. Student's T-test (SPSS) was used to compare between groups, assuming a normal distribution and unequal variance.

Super-resolution microscopy {#s4-5}
---------------------------

We have used the dSTORM system which allows for approximately 20 nm resolution by using photo-switchable fluorophores. 50μm-thick *Gli1-Cre^ERT2^*; Ai9 mouse brain slices were immunostained with anti-RFP (EnCor 1:300 PRID:[AB_2572308](http://antibodyregistry.org/AB_2572308)), anti laminin (Abcam 1:200, PRID:[AB_298179](http://antibodyregistry.org/AB_298179)) and anti CD31 (Bio-Rad 1:50, PRID:[AB_321653](http://antibodyregistry.org/AB_321653)). Secondary antibodies used: donkey Anti Chick Alexa Fluor568, donkey Anti-rabbit Alexa Fluor488 and donkey anti hamster Alexa Fluor647, all from Jackson Immunoresearch. After staining, brain slice was mounted on Poly-D-lysine coated coverslip (1.5H). dSTORM imaging was performed in a freshly prepared imaging buffer that contained 50 mM Tris (pH 8.0), 10 mM NaCl and 10% (w/v) glucose with an oxygen-scavenging GLOX solution (0.5 mg/ml glucose oxidase (Sigma-Aldrich), 40 μg/ml catalase (Sigma-Aldrich), 10 mM cysteamine MEA (Sigma-Aldrich) and 1% β mercaptoethanol [@bib8]. A Nikon Ti-E inverted microscope was used. The N- STORM Nikon system was built on TIRF illumination using 1.49 × 100 oil immersing objective and ANDOR DU-897 camera. 488, 568 and 647 nm laser line were used for activation with cycle repeat of∼5000 cycles. Nikon NIS Element software was used for collections the data; analysis was performed by ThunderSTORM ImageJ plugin ([@bib28]). Images in 2D were Gaussian fit of each localization. dSTORM signal at the ROI (enclosing the entire vessel) was normalized to the length of vessel circumference. All groups were tested for normal distribution using the Kolmogorov-Smirnov test. One-way ANOVA with Tukey's post-hoc analysis was used to compare between groups.

Tissue processing for electron microscopy {#s4-6}
-----------------------------------------

### For labeling RGLs {#s4-6-1}

Brains of *Gli1-Cre^ERT2^*; Ai9 mice (3 days post tamoxifen induction) were immersion-fixed by 4% paraformaldehyde (wt/vol); 0.1% glutaraldehyde (vol/vol) in 0.1M phosphate buffer; and kept at 4°C for 24 hr. The brain was then washed in PBS solution, and cut in 50 µm coronal sections with a vibratome (Leica). For the immunoperoxidase process, the tissue was washed 10 min in 3% H~2~O~2~ solution, blocked by two washes in 0.5% BSA and the sections were incubated overnight in the primary antibody (anti RFP, Abcam 1:400, PRID:[AB_945213](https://antibodyregistry.org/search.php?q=AB_945213)) in 0.1% BSA-PBS with shaking at 25°C. Next, sections were washed in PBS solution and incubated in the secondary antibody (anti-rabbit HRP, Vector MP-7451--50) shaking for 2 hr at 25°C. Sections were then washed in PBS solution and incubated in DAB/plus chromogen solution (Abcam ab103723) for 6--10 min, followed by subsequent washes in PBS solution (30 min).

### For systemic HRP imaging {#s4-6-2}

10 mg of HRP (Sigma P8250) was dissolved in 0.4 ml of PBS and injected into the tail vein of an adult (p90) mouse. After 30 min of HRP circulation, the brain was dissected and fixed by immersion in a 0.1 M sodium-cacodylate-buffered mixture (5% glutaraldehyde and 4% PFA) for 1 hr at room temperature followed by 5 hr at 4°C. Following fixation, the tissue was washed overnight in 0.1 M sodium cacodylate buffer and then cut in 50-µm-thick free-floating sections using a vibratome (Leica). Sections were incubated in DAB/plus chromogen solution (Abcam ab103723) for 6--10 min, followed by subsequent washes in PBS solution (30 min).

### For double-labeling of HRP and RGLs {#s4-6-3}

HRP was injected as above, processing was done as for labeling RGLs.

Stained brain slices were transferred back to the fixative solution, rinsed 4 times, 10 min each, in cacodylate buffer and post-fixed and stained with 1% osmium tetroxide, 1.5% potassium ferricyanide in 0.1M cacodylate buffer for 1 hr. Tissue was then washed 4 times in cacodylate buffer followed by dehydration in increasing concentrations of ethanol consisting of 30%, 50%, 70%, 80%, 90%, 95%, for 10 min each step followed by 100% anhydrous ethanol 3 times, 20 min each, and propylene oxide 2 times, 10 min each. Following dehydration, the tissue was infiltrated with increasing concentrations of Agar 100 resin in propylene oxide, consisting of 25, 50, 75, and 100% resin for 16 hr each step. The tissue was then embedded in fresh resin and let polymerize in an oven at 60°C for 48 hr. Embedded tissues in blocks were sectioned with a diamond knife on a Leica Reichert Ultracut S microtome and ultrathin sections (80 nm) were collected onto 200 Mesh, thin bar copper grids. The sections on grids were sequentially stained with Uranyl acetate for 5 min and Lead citrate for 2 min and viewed with Jeol JEM1400 Plus microscope equipped with Gatan camera.

Quantification of basement membrane coverage and vesicular-like structure {#s4-7}
-------------------------------------------------------------------------

55 EM images containing a blood vessel were used for quantification (N = 2 animals). Out of which, 50 were taken from the inner molecular layer and 5 were taken from the hilus area. The length of the blood vessel abluminal interface was measured by ImageJ (NIH). The length of BM (greyish line of \~50 nm thickness, clearly separating the endothelium from brain parenchyma (as in [Figure 2a](#fig2){ref-type="fig"})) was measured at both RGL contact point and when no RGL was present.

A circular structure of 50--100 nm in the cytoplasm of an endothelial cell encompassing a single membrane was counted as a vesicle. We counted the numbers of these organelles per length unit (μm) of the defined abluminal aspect (RGL/no RGL, BM/no BM). All groups were tested for normal distribution using the Kolmogorov-Smirnov test. One-way ANOVA with Tukey's post-hoc analysis was used to compare between groups.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"Hippocampal neural stem cells facilitate access from circulation via apical cytoplasmic processes\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Kate Wassum as the Senior and Reviewing Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Chenghua Gu (Reviewer \#1); Christer Betsholtz (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The data in this report demonstrate a unique and novel type of connection between neural stem cells of the brain\'s dentate gyrus and vascular endothelial cells of capillaries that feed this area. The data show that these contact sites function to actively deliver blood-borne molecules to the dentate gyrus cells. The chemotherapeutic agent doxorubicin is shown to be taken up specifically by dentate gyrus cells, and this leads to their reduced proliferation. These data, thus, explain why doxorubicin has cognitive side effects in spite of the fact that it should not pass the normal blood-brain barrier. These are significant novel discoveries of pathophysiological and physiological relevance. This manuscript opens new understanding of how systemic factors regulate dentate gyrus cell function in wanted and unwanted ways.

The reviewers noted the following concerns that must be thoroughly addressed.

1\) The increase of transcytotic vesicles at the touching points of endothelial cells and neural stem cells is not convincingly shown. A tracer that is detectable by EM, such as HRP, should be injected into circulation to demonstrate tracer uptake by transcytotic vesicles and neural stem cells. The transcytotic vesicles in endothelial cells in touch or not in touch with neural stem cells should be quantified. EM quality should be improved.

2\) The authors should quantify vesicle density in Figure 3 and confirm that these vesicles are related to transcytosis (clathrin or caveolar), and not incidental (e.g., lysosomes, Golgi vesicles).

3\) Basement membrane coverage of endothelial cells in touch or not in touch with neural stem cells needs to be quantified. The authors should quantify their TEM images to strengthen their claims about a thinned BM at the BV-RGL interface. The absence of a BM is not clear in Figure 2B, especially in the top-left image where a BM appears to continuously move upwards even at the BV-RGL interface, and in Figure 3. Moreover, Figure 2I-N of prior work from Moss, et al., 2016, appear to show a BM at the BV-RGL interface.

4\) Is the BM similarly thinned at BV areas covered by pericytes and astrocytes-or is this specific to RGLs? And is a BM similarly lacking in the BV-NSC interface in the SVZ? This would support specificity of BM thinning at the BV-RGL interface and thus claims regarding its role in the uptake of circulatory factors.

5\) The authors suggest that the BV-RGL interface is a \"fully functional BBB\" but that rapid uptake of injected dextrans and doxorubicin is mediated by a thinned BM at the BV-RGL interface. The literature would suggest that a fully functional BBB precludes the uptake of such factors by the brain endothelial cells, upstream of access to the BM. This has been found with dextrans, HRP, and endogenous plasma proteins. Please address this discrepancy. For example, the authors could replicate established experiments on these particular BVs to determine if they are indeed fully functional, such as looking for HRP+ vesicles in endothelial cells by TEM (e.g., Ben-Zvi et al., 2014, Figure 5) and staining for endogenous plasma protein uptake (e.g., PMID 28441414, Figure 6). Relatedly, functional brain BVs are also marked by \"extremely low rates of transcellular vesicular transport\" (Ben-Zvi et al., 2014). The authors are asked to reconcile this with their findings in Figure 3.

6\) The authors should tone down their conclusion or provide direct evidence for their claim that doxorubicin uptake by RGLs reduces their proliferation: do doxorubicin+ RGLs display less Ki67 and BrdU signal compared to doxorubicin- RGLs? Because doxorubicin fluoresces red, this should be visible in existing tissue slices from Figure 7B.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Hippocampal neural stem cells facilitate access from circulation via apical cytoplasmic processes\" for further consideration by *eLife*. Your revised article has been reviewed by two peer reviewers and the evaluation has been overseen by Kate Wassum as the Senior and Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) The newly introduced data in Figure 3 has been quantified by comparing blood vessels in the DG with blood vessels in cortex. It is unclear whether there are general differences of basement membrane coverage within different brain regions. Therefore, and also for consistency (with quantifications in Figures 2C/4D and E) it would be preferential to do the quantification by comparing BV-RGL contact points with non-contact points of blood vessels within the DG.

2\) Figure 2B top left panel shows a continuous basement membrane between EC and RGL. To be more representative of the quantified data and to better reflect the new finding, it would be beneficial to replace this image with an image showing a discontinued basement membrane at the RGL contact point.

3\) It is difficult to find orientation in Figure 4F top right panel. Maybe labeling of lumen and basement membrane would help. Ideally this image could be replace with an image that meets the quality of the other panels in this figure.

4\) It is unfortunate that the authors could not quantify tracer filled vesicles at RGL-BV contact points in comparison with non-contact points. This appears to be a crucial piece of data (as it was also demanded by more than one reviewer) to verify increased transcytotic activity (in a spatially very confined region). Would a double labeling of RGLs and HRP by DAB be possible? The labeled structures appear in different cells and are morphologically distinguishable. Alternatively, could this quantification be done by determining the region based on the absence of basement membrane?
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Author response

> \[...\] The reviewers noted the following concerns that must be thoroughly addressed.
>
> 1\) The increase of transcytotic vesicles at the touching points of endothelial cells and neural stem cells is not convincingly shown. A tracer that is detectable by EM, such as HRP, should be injected into circulation to demonstrate tracer uptake by transcytotic vesicles and neural stem cells. The transcytotic vesicles in endothelial cells in touch or not in touch with neural stem cells should be quantified. EM quality should be improved.
>
> 2\) The authors should quantify vesicle density in Figure 3 and confirm that these vesicles are related to transcytosis (clathrin or caveolar), and not incidental (e.g., lysosomes, Golgi vesicles).

We performed experiments with tail-vein injections of HRP and TEM imaging. These are presented in new Figure 4. We were able to demonstrate cytoplasmic and abluminal HRP-filled vesicles. These detection methods, however, are not sensitive enough to label HRP accumulation in non-endothelial cells. Additionally, since the same specimen cannot be labeled with DAB to both injected HRP and to RFP in stem cells, we could not pinpoint the specific location of BV-NSC contact in HRP-injected specimens.

In RFP-labeled TEM images, we quantified the density of vesicular-like structures at contact points (in comparison with areas with no NSC contact) and found a significantly higher density. These vesicular-like structures were determined as circular organelles of 60-100nm. We also quantified the densities of these structures in NSC-BV contact points with or without evident basement membrane and found a significantly higher number in areas without evident BM. All of these results appear in Figure 4.

> 3\) Basement membrane coverage of endothelial cells in touch or not in touch with neural stem cells needs to be quantified. The authors should quantify their TEM images to strengthen their claims about a thinned BM at the BV-RGL interface. The absence of a BM is not clear in Figure 2B, especially in the top-left image where a BM appears to continuously move upwards even at the BV-RGL interface, and in Figure 3. Moreover, Figure 2I-N of prior work from Moss, et al., 2016, appear to show a BM at the BV-RGL interface.

As suggested, we have quantified BM coverage at NSC-BV contact points in comparison with BV areas devoid of NSC, or in the hilus where no NSC processes exist. We found that in BV with no contacts, the majority of the abluminal aspect is surrounded by evident BM. At contact points, however, some areas do have a BM but the majority have not. These quantifications are presented in new Figure 2. Indeed, since these BM-reduced contacts are seemingly formed at specific points and not all through the NSC arm, Moss et al. presented an example of contacts that include a basement membrane (as we also do, see Figure 2C).

Figure 2B (left) was enlarged to better highlight the BM. The new image in Figure 4A better shows reduced BM at the contact points with two RGLs.

We added confocal and super-resolution microscopy images to further establish the finding of reduced BM components at contact points. New Figure 3 shows laminin immunostaining and uses both high magnification confocal images and STORM microscopy. New Figure 3---figure supplement 1 shows reduced Collagen IV staining at contact points.

> 4\) Is the BM similarly thinned at BV areas covered by pericytes and astrocytes-or is this specific to RGLs? And is a BM similarly lacking in the BV-NSC interface in the SVZ? This would support specificity of BM thinning at the BV-RGL interface and thus claims regarding its role in the uptake of circulatory factors.

We thank the reviewer for both of these suggestion. We have indicated in the revised manuscript (Figure 2A legends) that the BM is not thinned in contact points with pericytes and astrocytes. The pericytic contact point is characterized by a double layer of BM surrounding both the EC and the pericyte. In astrocytic endfeet (that accompany the majority of cerebral capillaries), the BM is clearly evident. Example for both is seen in Figure 2A.

We were unable to characterize the SVZ NSC-BV contact points in TEM as these contacts are rare and localized to the medial striatum near the lateral ventricles. However, we could neither identify the 10Kd tracer accumulation in SVZ NSC (see Figure 5A), therefore we believe that the case of the SVZ could be different. SVZ stem cells are also in contact with the CSF in ventricles (Mirzadeh et al., 2008) and most likely receive inputs by this route.

> 5\) The authors suggest that the BV-RGL interface is a \"fully functional BBB\" but that rapid uptake of injected dextrans and doxorubicin is mediated by a thinned BM at the BV-RGL interface. The literature would suggest that a fully functional BBB precludes the uptake of such factors by the brain endothelial cells, upstream of access to the BM. This has been found with dextrans, HRP, and endogenous plasma proteins. Please address this discrepancy. For example, the authors could replicate established experiments on these particular BVs to determine if they are indeed fully functional, such as looking for HRP+ vesicles in endothelial cells by TEM (e.g., Ben-Zvi et al., 2014, Figure 5) and staining for endogenous plasma protein uptake (e.g., PMID 28441414, Figure 6). Relatedly, functional brain BVs are also marked by \"extremely low rates of transcellular vesicular transport\" (Ben-Zvi et al., 2014). The authors are asked to reconcile this with their findings in Figure 3.

We understand that the terminology we used might not be accurate enough. We believe that BV-RGL contact points are characterized not only by thinned BM (Figure 2) but also by a higher vesicular activity (Figure 4). Therefore, while the majority of endothelial cells in the region indeed exhibit fully functional BBB properties, endothelial cells in contact with RGL (or even only sub-cellular sections of these cells) facilitate 'non-barrier' functions. In Figure 4, we now present HRP+ vesicles in endothelial cells. The density of vesicles at endothelial cells of the inner molecular layer is much higher than those published for capillaries elsewhere in the brain (e.g. Ben-Zvi et al., 2014).

Relevant text related to this issue was changed to better illustrate the exact hypothesis. We highlighted in the last two paragraphs of Introduction and the first paragraph of the Discussion that the hippocampus is thought to have a fully functioning BBB milieu while we found a sub-region in which the BBB is altered.

> 6\) The authors should tone down their conclusion or provide direct evidence for their claim that doxorubicin uptake by RGLs reduces their proliferation: do doxorubicin+ RGLs display less Ki67 and BrdU signal compared to doxorubicin- RGLs? Because doxorubicin fluoresces red, this should be visible in existing tissue slices from Figure 7B.

This is indeed a correct observation However, the protocol for doxorubicin labeling of stem cells is an acute intracardial injection. Since the chest is open, the mouse is sacrificed within 2 minutes and therefore the effect on stem cell proliferation cannot be measured. In contrast, the long-term doxorubicin exposure in the second setting used for NSC proliferation inhibition is three IP injections of doxorubicin, every other day. The doses reaching the brain in this protocol are not sufficient to be detected by fluorescence. We believe that doxorubicin accumulates equally in all NSC but affect only those who are engaged in proliferation. We added a text explaining this technical difference in dox protocols in the Results section. We also toned down this phrase in the Discussion and explained that dox potentially inhibit cell proliferation due to its penetrance to stem cells and maybe not solely by secondary mediators.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> 1\) The newly introduced data in Figure 3 has been quantified by comparing blood vessels in the DG with blood vessels in cortex. It is unclear whether there are general differences of basement membrane coverage within different brain regions. Therefore, and also for consistency (with quantifications in Figures 2C/4 and E) it would be preferential to do the quantification by comparing BV-RGL contact points with non-contact points of blood vessels within the DG.

As suggested, for the revised manuscript, we expanded the dSTORM-based analysis of blood vessels within the DG to include comparison between vessels with RGL association and vessels in the vicinity of RGLs with no RGL contacts. The data are presented in new Figure 3H-N, thereby also increasing the numbers of RGL-associated capillaries analyzed.

> 2\) Figure 2B top left panel shows a continuous basement membrane between EC and RGL. To be more representative of the quantified data and to better reflect the new finding, it would be beneficial to replace this image with an image showing a discontinued basement membrane at the RGL contact point.

We replaced this image to clearly demonstrate discontinued BM at the contact point with DAB-labeled RGL.

> 3\) It is difficult to find orientation in Figure 4F top right panel. Maybe labeling of lumen and basement membrane would help. Ideally this image could be replace with an image that meets the quality of the other panels in this figure.

As suggested, we replaced this image with a better quality image and also added labels to better explain the orientation. The new image includes examples of HRP-filled vesicles near a vague BM structure (presented in Figure 4E). For comparison, we included a representative image of HRP-filledcapillary lumen aligned with an astrocyte end-feet with a clear BM and no vesicular activity (Figure 4F).

> 4\) It is unfortunate that the authors could not quantify tracer filled vesicles at RGL-BV contact points in comparison with non-contact points. This appears to be a crucial piece of data (as it was also demanded by more than one reviewer) to verify increased transcytotic activity (in a spatially very confined region). Would a double labeling of RGLs and HRP by DAB be possible? The labeled structures appear in different cells and are morphologically distinguishable. Alternatively, could this quantification be done by determining the region based on the absence of basement membrane?

To address this important point, we followed the reviewer\'s suggestion to try a novel approach of double labeling for both RGLs termini and transcytotic endothelial vesicles with DAB (Immuno-EM with anti-RFP and secondary HRP conjugated antibody for RGL and HRP injected as tracer for vesicles). We have to admit that we found this approach technically challenging and not a trivial combination of the two protocols: Using Immuno-EM requires a very low fixative concentration, not ideal for achieving high-quality EM images. Moreover, immunostaining brain slices with anti-RFP antibody involves washing steps which interferes with the detection of HRP in BVs lumen. Nevertheless, we preformed the requested quantification based on HRP traces at the endothelial luminal surface and in vesicles. While not ideal, we believe the data indeed support the notion of increased transcytotic activity. These results are presented in Figure 4---figure supplement 1B-D.

[^1]: These authors contributed equally to this work.
